The fair value estimate for OraSure Technologies has increased from US$4.00 to US$5.50 per share, representing a meaningful change in how the stock is being valued today. This revised price target reflects renewed analyst discussion about whether stabilizing HIV and HCV testing trends and a potential inflection in the core business can offset execution and funding risks. Read on to see what is driving this evolving narrative and how you can monitor the key developments. Analyst Price Targets...
Collaboration will bring diagnostics expertise to a global, multi-stakeholder effort focused on policy, advocacy, and practical implementationBETHLEHEM, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic tests and sample management solutions, announced today that it has joined the World Coalition on Sickle Cell Disease, an international public-private partnership working to strengthen the global response to sickle cell disease.
BETHLEHEM, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its third quarter 2026 financial results on Monday, November 9, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5:00 p.m. Eastern Time on that day. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Pl
On August 5, OraSure Technologies (NASDAQ:OSUR) reported second-quarter 2026 results that included its first GAAP net income in years, a headline number of $6.2 million versus a $19.7 million loss a year earlier. Revenue of $30.6 million beat the company’s own guidance range and climbed 9.7% from the prior quarter. But look past the top […]
This is the newest page. Registered accounts read further back.